Format

Send to

Choose Destination
Int J Rheum Dis. 2018 Jan;21(1):161-169. doi: 10.1111/1756-185X.12934. Epub 2017 Feb 3.

A randomized multicenter clinical trial of 99 Tc-methylene diphosphonate in treatment of rheumatoid arthritis.

Author information

1
Department of Rheumatology & Immunology, Peking University People's Hospital, Beijing, China.
2
Department of Rheumatology & Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.
3
Department of Rheumatology & Immunology, Peking University First Hospital, Beijing, China.
4
Department of Rheumatology & Immunology, Peking University Third Hospital, Beijing, China.
5
Department of Rheumatology & Immunology, Beijing Hospital, Beijing, China.
6
Department of Rheumatology & Immunology, Xijing Hospital, Xijing, China.
7
Department of Rheumatology & Immunology, Xiangya Hospital Central South University, Changsha, China.
8
Department of Rheumatology & Immunology, The Third Affiliated Hospital, Sun Yat-Sen University, Anhui, China.
9
Department of Rheumatology & Immunology, Anhui Provincial Hospital, Hefei, Anhui, China.
10
Department of Rheumatology & Immunology, Qilu Hospital of Shandong University, Chengdu, Sichuan, China.
11
Department of Rheumatology & Immunology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
12
Institute of Clinical Trials, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Abstract

AIM:

To investigate the efficacy and safety of technetium-99 conjugated with methylene diphosphonate (99 Tc-MDP, Yunke Pharmaceutical industry) in the treatment of rheumatoid arthritis (RA).

METHODS:

A total of 120 patients with active RA were randomly divided into three groups: Group A (receiving oral meloxicam tablets); Group B (receiving intravenous drip of 99 TC-MDP); Group C (receiving combination treatment of intravenous drip of 99 Tc-MDP and oral meloxicam tablets). The main clinical and laboratory parameters were evaluated at baseline and after 14 days of therapy.

RESULTS:

After 14 days of treatment, American College of Rheumatology 20 response was 15.62%, 34.04% and 48.78% in the three groups, respectively. The incidence of adverse events in three groups were 3.13%, 8.51% and 9.76% respectly, and has no significant difference. In addition, biochemical markers of bone metabolism including bone alkaline phosphatase (BAP), tartrate resistant acid phosphatase (TRAP) and dickkopf-1 (DKK-1), all improved in the three groups, although more significant in Group B than Group A, and more significant in the combination group than monotherapy groups.

CONCLUSION:

99 Tc-MDP has good efficacy and safety in the treatment of active RA patients; the benefit was more remarkable when 99 Tc-MDP was combined with NSAIDs. 99 Tc-MDP may also have potential to improve bone metabolism.

KEYWORDS:

99Tc-MDP; clinical trial; rheumatoid arthritis

PMID:
29356462
DOI:
10.1111/1756-185X.12934
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center